Clinical/Translational Cancer Immunotherapy

Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
Samuel Peter Heilbroner, Reed Few, Tomas G Neilan, Judith Mueller, Jitesh Chalwa, Francois Charest, Somasekhar Suryadevara, Christine Kratt, Andres Gomez-Caminero, Brian Dreyfus

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e002545; DOI: 10.1136/jitc-2021-002545
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
Peter Kar Han Lau, Breon Feran, Lorey Smith, Arian Lasocki, Ramyar Molania, Kortnye Smith, Alison Weppler, Christopher Angel, Damien Kee, Prachi Bhave, Belinda Lee, Richard J Young, Amir Iravani, Hanxian Aw Yeang, Ismael A Vergara, David Kok, Kate Drummond, Paul Joseph Neeson, Karen E Sheppard, Tony Papenfuss, Benjamin J Solomon, Shahneen Sandhu, Grant A McArthur

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e002995; DOI: 10.1136/jitc-2021-002995
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
Joël Guigay, Keun-Wook Lee, Manish R Patel, Amaury Daste, Deborah J Wong, Sanjay Goel, Michael S Gordon, Martin Gutierrez, Ani Balmanoukian, Christophe Le Tourneau, Alain Mita, Damien Vansteene, Ulrich Keilholz, Patrick Schöffski, Hans Juergen Grote, Dongli Zhou, Marcis Bajars, Nicolas Penel

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e002998; DOI: 10.1136/jitc-2021-002998
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
Sumit K Subudhi, Bilal A Siddiqui, Ana M Aparicio, Shalini S Yadav, Sreyashi Basu, Hong Chen, Sonali Jindal, Rebecca S S Tidwell, Ashwin Varma, Christopher J Logothetis, James P Allison, Paul G Corn, Padmanee Sharma

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e002919; DOI: 10.1136/jitc-2021-002919
High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer
Hyung Soon Park, Yoo Min Kim, Sewha Kim, Won Suk Lee, So Jung Kong, Hannah Yang, Beodeul Kang, Jaekyung Cheon, Su-Jin Shin, Chan Kim, Hong Jae Chon

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e003353; DOI: 10.1136/jitc-2021-003353
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
Paul B Chapman, Vetri Sudar Jayaprakasam, Katherine S Panageas, Margaret Callahan, Michael A Postow, Alexander N Shoushtari, Jedd D Wolchok, Allison Betof Warner

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e003395; DOI: 10.1136/jitc-2021-003395
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
Yosuke Miyamoto, Toshiyuki Kozuki, Keisuke Aoe, Sae Wada, Daijiro Harada, Michihiro Yoshida, Jun Sakurai, Katsuyuki Hotta, Nobukazu Fujimoto

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e003288; DOI: 10.1136/jitc-2021-003288
Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
Kjersti Flatmark, Annette Torgunrud, Karianne G Fleten, Ben Davidson, Hedvig V Juul, Nadia Mensali, Christin Lund-Andersen, Else Marit Inderberg

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e003109; DOI: 10.1136/jitc-2021-003109
Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
Mitchell Evers, Marjolein Stip, Kaylee Keller, Hanneke Willemen, Maaike Nederend, Marco Jansen, Chilam Chan, Kevin Budding, Stefan Nierkens, Thomas Valerius, Friederike Meyer-Wentrup, Niels Eijkelkamp, Jeanette Leusen

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e003163; DOI: 10.1136/jitc-2021-003163
CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
Jing Gao, Zhengyi Wang, Wenqing Jiang, Yanni Zhang, Zhen Meng, Yanling Niu, Zhen Sheng, Chan Chen, Xuejun Liu, Xi Chen, Chanjuan Liu, Keren Jia, Cheng Zhang, Haiyan Liao, Jaeho Jung, Eunsil Sung, Hyejin Chung, Jingwu Z. Zhang, Andrew X. Zhu, Lin Shen

Journal for ImmunoTherapy of Cancer Jun 2023, 11 (6) e006704; DOI: 10.1136/jitc-2023-006704

Main menu

Clinical/Translational Cancer Immunotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Clinical/Translational Cancer Immunotherapy

Pages